Ole Köhler-Forsberg, MD, PhD, DMSc; Victoria Stiglbauer, MSc; Jelena Brasanac, MSc; et al.
free access
JAMA Psychiatry. 2023;80(12):1196-1207. doi:10.1001/jamapsychiatry.2023.2983
This systematic review and meta-analysis assesses all available evidence for use of antidepressants in depression comorbid with medical diseases.
Dogukan Koc, MD; Henning Tiemeier, MD, PhD; Bruno H. Stricker, PhD; et al.
free access
JAMA Psychiatry. 2023;80(12):1208-1217. doi:10.1001/jamapsychiatry.2023.3161
This cohort study examines whether intrauterine exposure to selective serotonin reuptake inhibitors and prenatal or postnatal depressive symptoms are associated with brain morphologic trajectory in offspring.
Johan Lundberg, MD, PhD; Thomas Cars, PhD; Erik Lampa, PhD; et al.
open access
JAMA Psychiatry. 2023;80(12):1218-1225. doi:10.1001/jamapsychiatry.2023.2833
This cohort study examines the outcomes and associated risk factors of suicidal behavior in patients with major depressive disorder.
Deidre M. Anglin, PhD; Adriana Espinosa, PhD; Jean Addington, PhD; et al.
free access
JAMA Psychiatry. 2023;80(12):1226-1234. doi:10.1001/jamapsychiatry.2023.2841
This cohort study examines the association between area-level ethnic density during childhood, perceived discrimination, and psychosis risk outcomes among ethnoracial minoritized individuals at clinical high risk for psychosis.
Samuel J. Dienel, PhD; Kevin F. Dowling, BA; Zackery Barile, MS; et al.
free access
JAMA Psychiatry. 2023;80(12):1235-1245. doi:10.1001/jamapsychiatry.2023.2972
This case-control study examines mRNA levels of somatostatin (SST) in the dorsolateral prefrontal cortex of postmortem brain specimens from patients with schizophrenia, bipolar disorder, and major depression disorder to assess whether alterations in SST levels are diagnosis specific and associated with cognitive dysfunction.
Sidhant Chopra, PhD; Ashlea Segal, PhD; Stuart Oldham, PhD; et al.
free access
JAMA Psychiatry. 2023;80(12):1246-1257. doi:10.1001/jamapsychiatry.2023.3293
This case-control study models the processes that explain spatial patterns of gray matter volume loss in different stages of psychotic illness and assesses whether certain brain regions act as putative epicenters from which volume loss spreads.
Yanakan Logeswaran, MSc; Jennifer Dykxhoorn, PhD; Christina Dalman, PhD; et al.
free access
JAMA Psychiatry. 2023;80(12):1258-1268. doi:10.1001/jamapsychiatry.2023.3220
This case-control study examines whether patients diagnosed with psychotic disorder or nonpsychotic bipolar disorder differed from a control group in their deprivation and population density trajectories.
Matthew S. Ellis, PhD; Kevin Y. Xu, MD, MPH; Vitor S. Tardelli, MD, MS, PhD; et al.
free access
JAMA Psychiatry. 2023;80(12):1269-1276. doi:10.1001/jamapsychiatry.2023.3145
This case-control study with crossover analysis assesses the differences between patients receiving and not receiving gabapentin alongside buprenorphine in the treatment of opioid use disorder and the drug-related poisoning risk associated with gabapentin.
Spruha Joshi, PhD, MPH; Bianca D. Rivera, MPH; Magdalena Cerdá, DrPH, MPH; et al.
free access
JAMA Psychiatry. 2023;80(12):1277-1283. doi:10.1001/jamapsychiatry.2023.3416
This cohort study examines the rates of fatal drug overdose in Oregon and Washington 1 year after implementation of policy changes eliminating or lower criminal charges for drug possession.